Ateios Systems licensed an ORNL technology for solvent-free battery component production using electron curing. Through Innovation Crossroads, Ateios continues to work with ORNL to enable readiness for production-quality battery components.
Used lithium-ion batteries from cell phones, laptops and a growing number of electric vehicles are piling up, but options for recycling them remain limited mostly to burning or chemically dissolving shredded batteries.
Scientists at ORNL used their expertise in quantum biology, artificial intelligence and bioengineering to improve how CRISPR Cas9 genome editing tools work on organisms like microbes that can be modified to produce renewable fuels and chemicals.
As current courses through a battery, its materials erode over time. Mechanical influences such as stress and strain affect this trajectory, although their impacts on battery efficacy and longevity are not fully understood.
ORNL has been selected to lead an Energy Earthshot Research Center, or EERC, focused on developing chemical processes that use sustainable methods instead of burning fossil fuels to radically reduce industrial greenhouse gas emissions to stem climate change and limit the crisis of a rapidly warming planet.
Seven entrepreneurs will embark on a two-year fellowship as the seventh cohort of Innovation Crossroads kicks off this month at ORNL. Representing a range of transformative energy technologies, Cohort 7 is a diverse class of innovators with promising new companies.
Scientist-inventors from ORNL will present seven new technologies during the Technology Innovation Showcase on Friday, July 14, from 8 a.m.–4 p.m. at the Joint Institute for Computational Sciences on ORNL’s campus.
Marm Dixit, a Weinberg Distinguished Staff Fellow at ORNL has received the 2023 Rosalind Franklin Young Investigator Award.
Following months of promising test results, battery researchers at ORNL are recommending that the solid-state battery industry focus on a technique known as isostatic pressing as it looks to commercialize next-generation batteries.
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.